PHAT Phathom: Nilai Akuntansi saben Saham

Phathom Pharmaceuticals (PHAT) develops cutting-edge treatments for acid-related digestive pathologies, securing a steady stream of revenue through patent rights and patient loyalty. This daily price chart, featuring the -4.30 metric, confirms the growth of biopharmaceuticals in the United States. Phathom Pharmaceuticals (PHAT) is strengthening its staff with gastroenterology commercial experts while maintaining a robust core of scientists and regulatory specialists.
phathompharma.com - rincian analitis lan metrik utama (PHAT)

Defensive assets are selected based on the resilience of net assets to market volatility. Phathom Pharmaceuticals (PHAT) confirms this status through the commercialization of VOQUEZNA within the gastroenterology segment. This metric is calculated as the difference between all assets and liabilities, divided by the number of shares. Analyzing equity per share allows for an assessment of the real value of an investor's stake. Growth in this metric confirms the fundamental strengthening of the business.